Tranzyme board to explore sale, other alternatives

Published on NewsOK Modified: February 8, 2013 at 6:39 am •  Published: February 8, 2013
Advertisement
;

DURHAM, N.C. (AP) — Tranzyme Inc.'s board of directors will explore a possible sale, merger or business combination for the drug developer, which recently ended research into its most advanced experimental treatment.

The Durham, N.C., company said Friday it has not decided on any specific alternative, and it has no time frame for completing its review.

Tranzyme has no drugs on the market. It said in December it would end a mid-stage study of a treatment for diabetic gastroparesis because it failed to do better than a placebo. Gastroparesis is a condition in which the stomach takes too long to clear out food.

The company also is developing possible treatments for diarrhea caused by chemotherapy and for metabolic diseases.

Tranzyme shares closed at 56 cents per share on Thursday.



Trending Now


AROUND THE WEB

  1. 1
    Best cities to launch a startup
  2. 2
    Drought-stricken California may restrict outdoor water use
  3. 3
    Eva Mendes, Ryan Gosling pregnancy sparks Twitter shock from fans - NY Daily News
  4. 4
    Advocates for blind, deaf want more from Apple
  5. 5
    World Cup Fan Scores Modeling Gig From Cheering
+ show more